; or (iii) the labeling of such drug does not reflect current legal and regulatory requirements. (2) The term exclusivity period , with respect to a drug approved under section 505(c), means the period by which the effective date of the approval of an application for a different drug product could be delayed, or the different drug product could otherwise be impacted, under clause (ii), (iii), or (iv) of section 505(c)(3)(E), clause (ii), (iii), or (iv) of section 505(j)(5)(F), or section 505A, 505E, or 527. (3) The term generic version means a drug approved under section 505(j), whose reference drug is a covered drug. (4) The term relevant accepted use means a use for a drug in clinical practice that is supported by evidence that could meet the standards for approval under section 505. (5) The term selected drug means a covered drug for which the Secretary has determined through the process under subsection (c) that the labeling should be updated because aspects of such labeling are outdated according to evidence that has become available regarding the conditions of use reflected in the approved labeling or to reflect one or more relevant accepted uses. (b) Identification of covered drug candidates for revision The Secretary may consider requiring changes to the labeling of drugs where such updates would benefit the public health. To assist in deciding whether to require labeling changes for covered drugs, the Secretary may do one or both of the following: (1) Enter into cooperative agreements or contracts with public or private entities to review the available evidence concerning such drugs. (2) Seek public input concerning such drugs, including input on whether there is a relevant accepted use in clinical practice that is not reflected in the approved labeling of such drugs or whether aspects of the labeling of such drugs is outdated according to evidence that has become available regarding the conditions of use reflected in the approved labeling by— (A) holding public meetings